Exelixis dips after Tecentriq/Cotellic combo fails in Phase III

Roche (SIX:ROG; OTCQB:RHHBY) and partner Exelixis Inc. (NASDAQ:EXEL) said Tecentriq atezolizumab plus Cotellic cobimetinib missed the primary endpoint of improving overall survival (OS) vs. Stivarga regorafenib in the Phase III IMblaze370 trial as

Read the full 330 word article

User Sign In